[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dysphonia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dysphonia":33},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,47,67,95,137,168,196,220,247],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100560656","usefulness-and-feasibility-of-ultrasound-in-office-laryngology-procedures-100560656",false,"NCT06579989","Usefulness and Feasibility of Ultrasound in Office Laryngology Procedures","Usefulness and Feasibility of Ultrasound in Office Laryngology Procedures: A Pilot Study","Inclusion Criteria:\n\n* US-Guided Injection for Neurogenic Cough:\n\n  1. Age over 18 years\n  2. Recommended to undergo superior laryngeal nerve block\n* US-Assessment of Superior Laryngeal Nerve Anatomy\n\n  1. Age over 18 years\n  2. No cough complaints\n* US-Assessment of Injectate Volume:\n\n  1. Documentation of unilateral vocal fold paresis\u002Fparalysis or atrophy\n  2. Age over 18 years\n  3. Recommended to undergo injection laryngoplasty\n* US-Assessment of Swallow:\n\n  1. Age over 18 years\n  2. Presents with swallowing complaints\n* US-Assessment of Normal Swallow:\n\n  1. Age over 18 years\n  2. Presents without swallowing complaints\n* US-Assessment of Voice:\n\n  1. Age over 18 years\n  2. Undergoing evaluation of voice problems\n\nExclusion Criteria:\n\n1. Age under 18 years and over 99 years\n2. Open neck wound including tracheostomy",true,"ALL","18 Years","99 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"NA","Investigators will assess the usefulness of using ultrasound in office procedures for laryngology interventions. Participants who qualify will be adults who are undergoing superior laryngeal nerve block, injection laryngoplasty, swallowing evaluation, voice evaluation and voice therapy.",[28,29,30,31,32,33],"Cough","Vocal Cord Atrophy","Vocal Cord Paresis","Vocal Cord Paralysis","Dysphagia","Dysphonia","NOT_YET_RECRUITING","2026-06-12",{"date":37,"type":38},"2026-06-16","ACTUAL",{"date":40,"type":22},"2027-01",{"date":42,"type":22},"2030-01",{"name":44,"class":45},"Weill Medical College of Cornell University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":46},"100476108","a-personalized-voice-restoration-device-for-patients-with-laryngectomy-100476108","NCT05479643","A Personalized Voice Restoration Device for Patients With Laryngectomy","A Pilot Study for a Novel and Personalized Voice Restoration Device for Patients With Laryngectomy","Inclusion Criteria:\n\nGroup A: Healthy Volunteers\n\n1. Adult subjects, 18 or older\n2. Without any voice impairments\n\nGroup B: Subjects with Aphonia or Dysphonia\n\n1. Adult subjects, 18 or older\n2. Documentation of severe dysphonia and\u002For aphonia, or a GRBAS score \\> 0 (GRBAS is a scale that can be used to assess voice quality of subjects who do not have a recorded history of dysphonia or aphonia. The GRBAS scale evaluates for grade, roughness, breathiness, asthenia, and strain).\n\nExclusion Criteria:\n\n\\- Group A: Healthy Volunteers\n\n1\\. Voice impairment\n\nGroup B: Subjects with Aphonia or Dysphonia\n\n1\\. Subjects whose face muscles are entirely paralyzed","110 Years",{"count":56,"type":22},100,[25],"The investigators will conduct a pilot experiment for a novel and personalized method for voice restoration using machine learning applied to surface EMG (sEMG) signal from articulatory muscles of the face and the neck allowing recognition of silent speech. The investigators predict that the use novel personalized method for voice restoration will be feasible and successful for patients.",[33,60],"Aphonia",{"date":37,"type":38},{"date":63,"type":22},"2027-12-01",{"date":65,"type":22},"2031-12",{"name":44,"class":45},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":23,"phases":76,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":46},"100638123","active-vs-passive-vr-during-office-based-ent-procedures-100638123","NCT07599826","Active vs. Passive VR During Office-based ENT Procedures","Active vs. Passive Virtual Reality for Reducing Pain and Anxiety During Office-based ENT Procedures","Inclusion Criteria Active and Passive VR:\n\n* Individuals 18 years old and older are included\n* Individuals undergoing the following common office-based ENT procedures: turbinate reduction, nasal debridement, balloon sinuplasty, radiofrequency ablation (Rhineaer\u002FVivaer), nasal polypectomy, eustachian tube dilation, vocal fold injection, or subglottic steroid injection\n* Able to consent\n* English speaking\n\nExclusion Criteria Active VR:\n\n* History of neurologic or seizure disorder, developmental delay, uncorrected visual impairment, motion sickness, vertigo, or inability to use a handheld controller\n* Any records flagged \"break the glass\" or \"research opt out.\"\n\nExclusion Criteria Passive VR:\n\n* History of neurologic or seizure disorder, developmental delay, uncorrected visual impairment, motion sickness, or vertigo\n* Any records flagged \"break the glass\" or \"research opt out.\"",{"count":75,"type":22},132,[25],"The purpose of this research is to evaluate whether active virtual reality reduces pain and anxiety more effectively than passive virtual reality during office-based ENT procedures. The main procedures include exposure to virtual reality (passive calming scenery or interactive puzzle game) via Paperplane Therapeutics software with VR headset or glasses during common in-office ENT procedures, participant self-report surveys (GAD-7, PHQ-9, PEG, VAS, SUDS, Likert, experience questions), and physician post-procedure survey. The study will enroll individuals 18 years or older who are scheduled to undergo common office-based ENT procedures (turbinate reduction, nasal debridement, balloon sinuplasty, radiofrequency ablation, nasal polypectomy, eustachian tube dilation, vocal fold injection, or subglottic steroid injection) at Cedars Sinai.",[79,80,81,82,83,84,33,85],"Pain","Anxiety","Chronic Rhinosinusitis (CRS)","Nasal Obstruction","Nasal Polyp","Eustachian Tube Dysfunction","Subglottic Stenosis (SGS)","2026-05-14",{"date":88,"type":38},"2026-05-20",{"date":90,"type":22},"2026-06",{"date":92,"type":22},"2027-12",{"name":94,"class":45},"Cedars-Sinai Medical Center",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":17,"minAge":102,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":23,"phases":105,"briefSummary":106,"conditions":107,"keywords":117,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100587890","phorte-therapy-efficacy-in-person-versus-telehealth-100587890","NCT06934265","PhoRTE® Therapy Efficacy: In-Person Versus Telehealth","Phonation Resistance Training Exercises (PhoRTE®) Delivered In-person and Via Telehealth: A Noninferiority Randomized Clinical Trial","Inclusion Criteria:\n\n* Adults 55+ with a primary diagnosis of presbyphonia, age-related voice changes, and\u002For vocal fold atrophy with or without localized loss of lamina propria (e.g. vocal fold scar)\n* Telehealth-capable device (e.g., tablet, computer) with microphone, speaker, camera, high-speed internet\n* Ability to attend four telehealth or in-person sessions for four consecutive sessions\n* Ability to attend two in-person evaluation sessions (pre- and post-treatment)\n\nExclusion Criteria:\n\n* Presence of localized masses, lesions, or vocal fold motion impairments identified during videostroboscopy at initial evaluation\n* Progressive neurologic conditions, e.g. Parkinson's disease (PD), Amyotrophic lateral sclerosis (ALS), Progressive supranuclear palsy (PSP), etc.\n* Previous attendance to exuberant voice therapy (e.g., PhoRTE, Lee Silverman Voice Treatment)\n* Untreated hearing loss\n* Non-English speakers","54 Years",{"count":104,"type":22},30,[25],"This study compares how well voice therapy works when delivered in-person versus through telehealth for older adults with age-related voice problems. Researchers are testing whether Phonation Resistance Training Exercises (PhoRTE®) can be just as effective when delivered remotely as when done face-to-face, which could make treatment more accessible and affordable for seniors.\n\nThe two primary hypotheses are:\n\n1. Does voice therapy (called PhoRTE®) work as well through video calls as it does face-to-face?\n2. Can online therapy be a more accessible way for older adults to get help for their voice problems?\n\nAdults aged 55 or older with voice changes and an applicable diagnosis will be randomly assigned to receive either in-person or telehealth therapy, consisting of four 45-minute sessions. After treatment, researchers will measure improvements through:\n\n* Changes in voice function\n* Patient reports about their voice\n* Scientific measurements of voice quality\n* Patient satisfaction with treatment\n* Impact on quality of life\n\nThe results will help determine if telehealth can be a good alternative to in-person voice therapy, especially important as telehealth coverage may be changing.",[108,109,33,110,111,112,113,114,115,116],"Atrophy of Vocal Cord","Presbyphonia","Glottic Insufficiency","Voice Change","Voice Disorder","Adults","Aging","Speech Therapy","Voice Alteration",[118,119,120,121,122,123,124,125,126],"Vocal fold atrophy","voice therapy","presbyphonia","aging voice","voice rehabilitation","speech pathology","Intervention","voice","aging","2026-01-09",{"date":129,"type":38},"2026-01-13",{"date":131,"type":22},"2026-01-25",{"date":133,"type":22},"2026-10-25",{"name":135,"class":45},"University of Southern California",4,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":4,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":46},"100463645","clinical-validation-of-dystonianet-deep-learning-platform-for-diagnosis-of-isolated-dystonia-100463645","NCT05317390","Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia","Inclusion criteria:\n\n1. Males and females of diverse racial and ethnic backgrounds, with age across the lifespan;\n2. Patients will have at least one of the forms of dystonia, including focal dystonia (e.g., laryngeal, cervical, oromandibular, blepharospasm, focal hand, musicians), segmental dystonia, or generalized dystonia;\n3. Patients will have other movement disorders (Parkinson's disease, essential tremor, dyskinesia, myoclonus) and other non-neurological conditions (tic disorders, torticollis, ulnar nerve entrapments, temporomandibular disorders, dysphonia) that mimic dystonic symptoms.\n\nExclusion criteria:\n\n1. Patients who are incapable of giving informed consent;\n2. Patients who are unable to undergo brain MRI due to the presence of certain tattoos and ferromagnetic objects in their bodies (e.g., implanted stimulators, surgical clips, prosthesis, artificial heart valve) that cannot be removed or due to pregnancy or breastfeeding at the time of the study.",{"count":144,"type":22},1000,[25],"This research involves retrospective and prospective studies for clinical validation of a DystoniaNet deep learning platform for the diagnosis of isolated dystonia.",[148,149,150,151,152,153,154,155,156,157,33],"Dystonia","Drug Induced Dystonia","Parkinson Disease","Essential Tremor","Dyskinesias","Myoclonus","Tic Disorders","Torticollis","Ulnar Nerve Entrapment","Temporomandibular Joint Disorders","RECRUITING","2025-11-24",{"date":161,"type":38},"2025-12-02",{"date":163,"type":38},"2022-06-01",{"date":165,"type":22},"2028-04-30",{"name":167,"class":45},"Massachusetts Eye and Ear Infirmary",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":174,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":23,"phases":178,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":46},"100606548","deconstructing-voice-therapy-towards-enhanced-communication-outcomes-100606548","NCT07176988","Deconstructing Voice Therapy: Towards Enhanced Communication Outcomes","Inclusion Criteria:\n\n* Non-smoking\n* Diagnosis of either primary muscle tension dysphonia of the hyperadducted type or benign vocal fold lesions.\n* No neuro-laryngologic or age-related vocal fold changes (e.g., atrophy)\n* No history of voice therapy or voice surgery in the last year\n* No history of other serious chronic medical conditions that may affect voice (per patient report), Normal hearing (determined by pure tone audiometry), stimulable and appropriate for behavioral voice intervention as determined by a voice-specialized speech-language pathologist and laryngologist,\n* Willingness to attend all therapeutic interventions and follow-up sessions\n* Willingness to use a smartphone to record practice\n\nExclusion Criteria:\n\n* History of voice therapy or voice surgery in the last year\n* Serious chronic medical condition that may affect voice (per patient report)\n* Abnormal hearing ability (despite appropriate amplification)\n* Other laryngeal disorders not attributed to primary MTD and benign vocal fold lesions,\n* Not stimulable or inappropriate for behavioral voice intervention as determined by a voice-specialized speech-language pathologist and laryngologist\n* Unwillingness to attend therapeutic intervention and follow-up sessions\n* Unwillingness to use a smartphone to record practice\n* Pregnant women\n* Prisoners\n* Cognitive impairment or impaired decision-making capacity","16 Years","65 Years",{"count":177,"type":22},120,[25],"This research study aims to evaluate the effect of treatment delivery method on voice outcomes over 12 months in people with a primary complaint of a voice problem, diagnosed with either non-phonotraumatic vocal hyperfunction, also known as primary muscle tension dysphonia (MTD) or phonotraumatic vocal hyperfunction, also known as benign vocal fold lesions (lesions).\n\nThe secondary objectives are:\n\n* To evaluate acoustic correlates of clear speech and the relationship to vocal acoustic and patient-reported voice outcomes.\n* To determine the association between overall dysphonia outcomes and adoption of clear speech.",[33,181],"Primary Muscle Tension Dysphonia (MTD)",[183,184,185,186],"Conversation Training Therapy","Hierarchical Conversation Training Therapy","primary muscle tension dysphonia","benign vocal fold lesions","2025-10-15",{"date":189,"type":38},"2025-10-20",{"date":191,"type":38},"2025-09-03",{"date":193,"type":22},"2029-04",{"name":195,"class":45},"Emory University",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":200,"acronym":4,"eligibilityCriteria":201,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":23,"phases":203,"briefSummary":205,"conditions":206,"keywords":208,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":46},"100604097","phase-3-translaryngeal-vibration-for-hyperfunctional-voice-disorders-100604097","NCT07145086","Translaryngeal Vibration for Hyperfunctional Voice Disorders","Inclusion Criteria:\n\n* a) diagnosis by an otolaryngologist of hyperfunctional dysphonia (MTD) without benign mid-membranous lesion (i.e., primary MTD or non-phonotraumatic hyperfunction) with and a recommendation for voice therapy, ((b) confirmation of dysphonia by a comprehensive voice evaluation conducted by a speech-language pathologist with experience in the evaluation and treatment of voice disordered populations, (c) to prevent floor effects of our primary outcome variable, participants will be required to exhibit a pre-treatment VHI score of \\>20, as this is the upper range for normal cutoff values in studies which have demonstrated high sensitivity and specificity for this tool (Behlau et al., 2016), (d) 18 years of age or older, (e) no history of local vibration therapy as part of a rehabilitation treatment program.\n\nExclusion Criteria:\n\n* Unable to receive vibration to neck area",{"count":104,"type":22},[204],"PHASE3","Contemporary treatments for hyperfunctional voice disorders such as muscle tension dysphonia (MTD) are effective but typically do not restore voice handicap or voice function to normal thresholds. Recent reports of vibration as a voice therapy modality have been published, but many questions remain about the efficacy of this tool. The current project addresses these problems through a blinded and randomized controlled trial to investigate the efficacy of local translaryngeal vibration for MTD and the dose-response relationship of this modality when compared to treatment without vibration.",[33,207],"Muscle Tension Dysphonia",[33,207,209,210],"Voice Therapy","Vibration","2025-08-20",{"date":213,"type":38},"2025-08-28",{"date":215,"type":38},"2024-09-01",{"date":217,"type":22},"2027-08-31",{"name":219,"class":45},"Texas Christian University",{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":228,"enrollmentInfo":229,"targetDuration":4,"studyType":23,"phases":231,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":46},"100592910","phase-4-the-mechanism-versus-ppi-trial-100592910","NCT06999577","The Mechanism Versus PPI Trial","The MVP Trial: A Randomized Controlled Trial of Mechanism Guided vs PPI Strategy for Laryngopharyngeal Reflux","MVP","Inclusion Criteria:\n\n1. 18-89 years of age\n2. \\>8 weeks of laryngeal symptoms (cough, throat clearing, dysphonia)\n3. Standard evaluation for LPR, undergoing EGD (with endoscopic evaluation of the hypopharynx) and reflux monitoring off acid suppression\n4. Off acid suppression therapy for at least 2 weeks prior to randomization.\n\nExclusion Criteria:\n\n1. PPI intolerance and\u002For known hypersensitivity to the formulation or substituted benzimidazoles\n2. History of foregut surgery\n3. Known diagnosis of achalasia\n4. Inability to fast for 4 hours (no food or drink)\n5. Active tobacco use\n6. Pregnant or breastfeeding\n7. Unable to consent in English or Spanish\n8. Unable to provide consent without a legal guardian or representative\n9. Imprisoned\n10. Endoscopic findings conclusive with esophageal mucosal abnormalities\n11. Unable to proceed with reflux monitoring\n12. Use of acid suppression during the reflux monitoring and\u002For before the study medication (omeprazole or placebo) is dispensed\n13. Prior LRT for reflux related symptoms\n14. History of major psychiatric comorbidity\n15. Unable to attend in person study visits at UCSD","89 Years",{"count":230,"type":22},160,[232],"PHASE4","The goal of this clinical trial is to learn if a mechanism guided strategy that utilizes a multidisciplinary approach to treat adults patients (age 18-89) with chronic throat symptoms who are undergoing clinical evaluation for laryngopharyngeal reflux (LPR) is more effective than the usual care strategy with proton pump inhibitor (PPI) therapy used in gastroenterology for these patients.\n\nThe main question it aims to answer is: Will a greater proportion of the mechanism guided strategy participants achieve symptom response in comparison to the usual care strategy participants?\n\nIf there is a comparison group: Researchers will compare the mechanism guided strategy to usual care strategy to see if treatment response differs between the groups.\n\nParticipants will be be asked to do the following:\n\n* participate in an 8-week blinded study phase where they will be randomized to either 1) Mechanism Guided Strategy or 2) Usual Care Strategy\n* take an oral capsule daily (omeprazole 40mg or placebo)\n* come to 3 in-person visits at UC San Diego Health for an intervention visit with a study provider\n* consider incorporating recommended lifestyle modifications\n* complete weekly surveys",[235,28,236,33,237],"Laryngopharyngeal Reflux","Throat Clearing","Reflux","2025-07-29",{"date":240,"type":38},"2025-08-01",{"date":242,"type":38},"2025-06-04",{"date":244,"type":22},"2029-07-01",{"name":246,"class":45},"University of California, San Diego",{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":257,"phases":4,"briefSummary":258,"conditions":259,"keywords":4,"overallStatus":158,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":46},"100576016","characterization-of-bamboo-and-other-vocal-cord-lesions-responsible-for-dysphonia-in-patients-with-systemic-autoimmune-diseases-bamboo-100576016","NCT06779799","Characterization of \"Bamboo\" and Other Vocal Cord Lesions Responsible for Dysphonia in Patients With Systemic Autoimmune Diseases (BAMBOO)","Characterization of \"Bamboo\" and Other Vocal Cord Lesions Responsible for Dysphonia in Patients With Systemic Autoimmune Diseases.","BAMBOO","Inclusion Criteria:\n\n* Patients aged 18 years or older\n* With a systemic autoimmune disease : rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, primary Sjogren disease, sarcoidosis, vasculitis, myositis, Still disease, Sharp syndrome.\n* Suffering from dysphonia.\n* With a cord vocal\u002Flaryngeal lesion highlighted.\n\nExclusion Criteria:\n\n* Patients under the age of 18 years\n* Dysphonia due to a cord vocal palsy related to a neurological condition or malignancy\n* History of cervical radiation\n* History of oro-tracheal intubation\n* Laryngeal cancer\n* Participation deny\n* Impossibility of consent\n* Patients with legal protection",{"count":256,"type":22},150,"OBSERVATIONAL","The goal of this multicenter retrospective observational study is to provide an inventory of the specific and non specific cord vocal lesions that can cause dysphonia in patients with systemic autoimmune diseases. The main question it aims to answer is:\n\n* What are the main cord vocal lesions responsible for dysphonia in patients with a systemic autoimmune disease?\n* Is there a diagnosis delay regarding those lesions?\n* How are those lesions managed? Participants suffering from dysphonia in a context of a systemic autoimmune disease will be identified, with a review of their medical record.",[33,260,261],"Connective Tissue Disease","Vasculitis","2025-01-13",{"date":264,"type":38},"2025-01-17",{"date":266,"type":38},"2024-12-01",{"date":268,"type":22},"2025-05-31",{"name":270,"class":45},"University Hospital, Brest"]